Genomic Profiling of Small Cell Neuroendocrine Prostate Cancer and its Implications for Targeted Therapies
This study is the first to reveal the SCPC genomic landscape in Japanese patients. Although genomic mutations, including DDR mutations, were not predictive of platinum-based chemotherapy efficacy, active genomic testing may improve access to targeted therapies for this challenging malignancy, especially where treatment options are limited.
Authors
- Hideto Ueki (ORCID: https://orcid.org/0000-0002-7742-4528)
- Junichiro Hirata
- Yukari Bando (ORCID: https://orcid.org/0000-0001-7736-1216)
- Naoe Jimbo (ORCID: https://orcid.org/0000-0003-0423-3568)
- Takuto Hara (ORCID: https://orcid.org/0000-0003-4524-2815)
- Tomoaki Terakawa (ORCID: https://orcid.org/0000-0002-4447-6516)
- Yasuyoshi Okamura (ORCID: https://orcid.org/0000-0002-8466-3949)
- Kōji Chiba (ORCID: https://orcid.org/0000-0001-7600-7813)
- H. Miyake (ORCID: https://orcid.org/0000-0001-9572-5124)
- Kotaro Suzuki (ORCID: https://orcid.org/0000-0003-4589-9251)
- Jun Teishima (ORCID: https://orcid.org/0000-0001-8429-1607)
Institutions
- Kobe University (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-03-01
- DOI
- https://doi.org/10.21873/anticanres.17501
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00